ライフサイエンスコーパス: invasive aspergillosis

1 killing and, in turn, host susceptibility to invasive aspergillosis.

2 ungal burden in a neutropenic mouse model of invasive aspergillosis.

3 causal agent of the life-threatening disease invasive aspergillosis.

4 demonstrating improved outcomes of treating invasive aspergillosis.

5 osphamide-treated BALB/c mice with cutaneous invasive aspergillosis.

6 gliotoxin contributes to pathogenesis during invasive aspergillosis.

7 n synthesis and are used clinically to treat invasive aspergillosis.

8 ce of EAPCRI protocols in an animal model of invasive aspergillosis.

9 or amphotericin B formulation as therapy for invasive aspergillosis.

10 corticosteroid-immunosuppressed mice against invasive aspergillosis.

11 iconazole has become the agent of choice for invasive aspergillosis.

12 apy is increasingly used in the treatment of invasive aspergillosis.

13 y available nonculture method for diagnosing invasive aspergillosis.

14 detection of invasive Candida infection and invasive aspergillosis.

15 diagnostic and therapeutic interventions in invasive aspergillosis.

16 ly deficit in CCR4 (CCR4-/-) did not develop invasive aspergillosis.

17 system, leading to the false presumption of invasive aspergillosis.

18 rulence of the wild type in a mouse model of invasive aspergillosis.

19 ature of the echinocandins, particularly for invasive aspergillosis.

20 1/CCL2 in the lungs of neutropenic mice with invasive aspergillosis.

21 posed them to doxycycline after the onset of invasive aspergillosis.

22 vising future therapeutic strategies against invasive aspergillosis.

23 ere the most common radiographic findings in invasive aspergillosis.

24 portant role in normal host defenses against invasive aspergillosis.

25 ms were associated with significant risk for invasive aspergillosis.

26 toxocariasis, congenital toxoplasmosis, and invasive aspergillosis.

27 r donors for PTX3 SNPs modifying the risk of invasive aspergillosis.

28 ehold as potential source of azole-resistant invasive aspergillosis.

29 protects CGD mice from colitis and also from invasive aspergillosis.

30 antly reduced virulence in a murine model of invasive aspergillosis.

31 rum GM quantification for early detection of invasive aspergillosis.

32 ecisions in patients with triazole-resistant invasive aspergillosis.

33 iconazole treatment failure in patients with invasive aspergillosis.

34 roup criteria classified these as "probable" invasive aspergillosis.

35 es in immunocompromised patients who develop invasive aspergillosis.

36 from those of the more commonly encountered invasive aspergillosis.

37 ing as a causative agent of life-threatening invasive aspergillosis.

38 ith an increase in the 3-year probability of invasive aspergillosis (12% vs. 1%, P=0.02) and death th

39 fungal infections (36% vs. 7%, P=0.0007) and invasive aspergillosis (14% vs. 2%, P=0.02) was signific

40 ccesses by type of IFI included 7 of 12 with invasive aspergillosis, 2 of 2 with invasive fusariosis,

41 15), Pseudomonas aeruginosa (27%, 4 of 15), invasive aspergillosis (20%, 3 of 15), and Enterobacter

42 Of these, 158 had invasive aspergillosis, 44 were colonized, and 12 had co

43 illus fumigatus) is the most common cause of invasive aspergillosis, a frequently fatal lung disease

44 Aspergillus fumigatus causes invasive aspergillosis, a potentially fatal infection in

45 It has previously been reported that invasive aspergillosis, a prototypic opportunistic infec

46 be licensed was caspofungin, for refractory invasive aspergillosis (about 40% response rate) and the

47 haplotypes (S3 and S4) increased the risk of invasive aspergillosis (adjusted hazard ratio for S3, 2.

48 onor haplotype S4 also increased the risk of invasive aspergillosis (adjusted odds ratio, 2.49; 95% C

49 ifungal immunity result in increased risk of invasive aspergillosis after chemotherapy or transplanta

50 orphisms were shown to influence the risk of invasive aspergillosis among hematopoietic stem cell tra

51 of TLR polymorphisms in conferring a risk of invasive aspergillosis among recipients of allogeneic he

52 the donor TLR4 haplotype S4 and the risk of invasive aspergillosis among recipients of hematopoietic

53 ulticenter study involving 107 patients with invasive aspergillosis and 223 matched controls.

54 tudy patients had fungal pneumonitis; 4% had invasive aspergillosis and 3% had cryptococcosis.

55 deficiency type I confer a predisposition to invasive aspergillosis and candidiasis.

56 invasive fungal disease (IFD), particularly invasive aspergillosis and candidiasis.

57 s a critical early host defense mechanism in invasive aspergillosis and demonstrate NK cells to be an

58 tigated the role of TLR9 in murine models of invasive aspergillosis and fungal asthma.

59 ine dilution into account, reliably detected invasive aspergillosis and may be a promising diagnostic

60 It is approved for the treatment of invasive aspergillosis and mucormycosis.

61 Invasive aspergillosis and other fungal infections occur

62 escribe the case of a patient with improving invasive aspergillosis and paradoxically rising serum ga

63 Furthermore, nosocomial infections such as invasive aspergillosis and Pseudomonas aeruginosa occurr

64 Enterobacter bacteremia, invasive aspergillosis, and disseminated Candida infecti

65 fungal infections, invasive mold infections, invasive aspergillosis, and invasive candidiasis during

66 tional amphotericin B as primary therapy for invasive aspergillosis, and is the new standard of care

67 as performed, radiology data consistent with invasive aspergillosis, and the timing of initiation of

68 early IFN-gamma in the lungs in neutropenic invasive aspergillosis, and this is an important mechani

69 to be effective in reducing the incidence of invasive Aspergillosis as compared with no prophylaxis.

70 We developed invasive aspergillosis (Aspergillus fumigatus) and mucor

71 were free of IFD, invasive candidiasis, and invasive aspergillosis at 1 year.

72 is considered a significant risk factor for invasive aspergillosis but is almost always associated w

73 action may facilitate the early diagnosis of invasive aspergillosis, but have limitations.

74 NK cells mediate their protective effect in invasive aspergillosis by acting as the major source of

75 above the threshold considered positive for invasive aspergillosis by the recently licensed double s

76 Invasive aspergillosis carries a high mortality with a r

77 rate variability in the numbers of diagnosed invasive aspergillosis cases in oncology centers, and a

78 A recent report on several cases of invasive aspergillosis caused by Neosartorya udagawae su

79 Invasive aspergillosis causes significant mortality amon

80 festations of Aspergillus infections include invasive aspergillosis, chronic pulmonary aspergillosis

81 ransplant recipients with proven or probable invasive aspergillosis collected as part of the Transpla

82 CMC, invasive candidiasis, invasive aspergillosis, deep dermatophytosis, pneumocyst

83 Finally, in the context of neutropenic invasive aspergillosis, depletion of DCs resulted in imp

84 Invasive aspergillosis develops in immunocompromised pat

85 Eight patients presented with invasive aspergillosis due to TR46/Y121F/T289A, and trea

86 embolism, pneumonia, secondary peritonitis, invasive aspergillosis, endocarditis and myocardial infa

87 , A. fumigatus is the most frequent agent of invasive aspergillosis, followed by A. lentulus and A. v

88 ients with a potentially low pretest risk of invasive aspergillosis following effective antimold prop

89 has been used as an aid in the diagnosis of invasive aspergillosis for almost 2 decades.

90 d comparison clinical trial for treatment of invasive aspergillosis found that the efficacy of isavuc

91 infections is still limited, mouse models of invasive aspergillosis fulfill a critical void for study

92 poorly defined in patients with GM-positive invasive aspergillosis (GPA).

93 ared them with contemporaneous patients with invasive aspergillosis (group B; n = 54) and with matche

94 cy of the echinocandins for the treatment of invasive aspergillosis has been based on historically co

95 Invasive aspergillosis has emerged as an important cause

96 Because outbreaks of invasive aspergillosis have been linked to hospital cons

97 branching hyphae, suggesting a diagnosis of invasive aspergillosis; however, occasional yeast-like c

98 Patients with invasive aspergillosis (IA) (3/3) had positive GM at bas

99 unit (ICU) patients with probable or proven invasive aspergillosis (IA) and 100 ICU patients without

100 l study, 211 samples from 10 proven/probable invasive aspergillosis (IA) and 2 possible IA cases and

101 entified 93 patients with proven or probable invasive aspergillosis (IA) and GM values of >or=0.50 fr

102 Outbreaks of invasive aspergillosis (IA) are believed to be caused by

103 iral therapy (cART), roughly 50% of cases of invasive aspergillosis (IA) associated with human immuno

104 Strict definition of invasive aspergillosis (IA) cases is required to allow p

105 dy, 124 DNA extracts from 14 proven/probable invasive aspergillosis (IA) cases, 2 possible IA cases,

106 The outcome of invasive aspergillosis (IA) continues to be associated w

107 Delayed diagnosis in invasive aspergillosis (IA) contributes to its high mort

108 Screening of high-risk patients for invasive aspergillosis (IA) has the potential to decreas

109 methodologies for the molecular detection of invasive aspergillosis (IA) have been established by the

110 The incidence of postengraftment invasive aspergillosis (IA) in hematopoietic stem cell t

111 s DNA for the early diagnosis and therapy of invasive aspergillosis (IA) in high-risk hematological p

112 r screening is increasingly used to diagnose invasive aspergillosis (IA) in high-risk patients.

113 hoalveolar lavage (BAL) for the diagnosis of invasive aspergillosis (IA) in lung transplant recipient

114 The most common cause of invasive aspergillosis (IA) in patients with chronic gra

115 Despite suffering an outbreak of invasive aspergillosis (IA) in the intensive care unit d

116 Invasive aspergillosis (IA) is a frequent complication o

117 Invasive aspergillosis (IA) is a life-threatening infect

118 Invasive aspergillosis (IA) is a life-threatening system

119 Invasive aspergillosis (IA) is a significant cause of mo

120 Invasive aspergillosis (IA) is an important cause of mor

121 Invasive aspergillosis (IA) is associated with poor outc

122 Invasive aspergillosis (IA) is rare among renal transpla

123 Invasive aspergillosis (IA) is the most important opport

124 The testing of an animal model of invasive aspergillosis (IA) overcomes the low incidence

125 Invasive aspergillosis (IA) remains a leading cause of m

126 Invasive aspergillosis (IA) remains a leading cause of m

127 Diagnosis of invasive aspergillosis (IA) remains challenging.

128 Invasive aspergillosis (IA) resulting from infection by

129 he most devastating infections after HSCT is invasive aspergillosis (IA), a life-threatening disease

130 8 ng/ml) of mice with experimentally induced invasive aspergillosis (IA), and levels decreased with a

131 Transplant recipients are at risk for invasive aspergillosis (IA), associated with a significa

132 onic necrotizing pulmonary aspergillosis, or invasive aspergillosis (IA), depending on the host's imm

133 ollowing four groups of patients: those with invasive aspergillosis (IA), those with other mold infec

134 ods have long been used for the diagnosis of invasive aspergillosis (IA), variable performance in cli

135 s, and A. terreus, account for most cases of invasive aspergillosis (IA), with A. nidulans, A. niger,

136 EIA) is widely utilized for the diagnosis of invasive aspergillosis (IA).

137 ression of one such ligand, KC, in mice with invasive aspergillosis improves the outcome of disease.

138 reviews the presentation and epidemiology of invasive aspergillosis in children and adolescents with

139 ergillus fumigatus, the predominant agent of invasive aspergillosis in immunocompromised hosts.

140 necessary for effective host defense against invasive aspergillosis in immunocompromised hosts.

141 man fungal pathogen causing life-threatening invasive aspergillosis in immunocompromised patients.

142 tions have been used for prophylaxis against invasive aspergillosis in lung transplant recipients.

143 The outcome of invasive aspergillosis in mice treated with each agent w

144 hat the absence of CCR7 is protective during invasive aspergillosis in neutropenic mice.

145 nd CCL22, two CCR4 ligands, during pulmonary invasive aspergillosis in neutropenic mice.

146 t the Axl mAb treatment is protective during invasive aspergillosis in neutropenic mice.

147 caspofungin when used as primary therapy for invasive aspergillosis in organ transplant recipients ha

148 eutrophils and may contribute to the risk of invasive aspergillosis in patients treated with HSCT.

149 might be of great value in the clearance of invasive aspergillosis in patients with CGD.

150 ession may not be a relevant risk factor for invasive aspergillosis in the 1990s due to less frequent

151 The low pretest risk of invasive aspergillosis in the context of effective antim

152 o be the "gold standard" in the treatment of invasive aspergillosis in the immunocompromised host.

153 he immunocompetent host but can cause lethal invasive aspergillosis in the immunocompromised host.

154 ver a potential mechanism for development of invasive aspergillosis in the setting of CGD and cortico

155 ssessed the performance of any PCR assay for invasive aspergillosis in whole blood or serum and that

156 Risk factors for invasive aspergillosis include prolonged and severe neut

157 The incidence of invasive aspergillosis increased from 5.7% to 11.2% duri

158 se antigens expanded in patients with active invasive aspergillosis, indicating their contribution to

159 lly bioavailable agents for the treatment of invasive aspergillosis, invasive candidiasis, cryptococc

160 Invasive aspergillosis is a common and devastating pneum

161 icin B and triazoles is antagonistic against invasive aspergillosis is a controversial issue that is

162 Invasive aspergillosis is a deadly infection for which n

163 Invasive aspergillosis is a difficult-to-diagnose infect

164 Invasive aspergillosis is a leading cause of infectious

165 Invasive aspergillosis is a life-threatening complicatio

166 Invasive aspergillosis is a major threat to patients wit

167 protects immunocompromised patients against invasive aspergillosis is a novel approach to a universa

168 Invasive aspergillosis is a serious infectious complicat

169 Invasive aspergillosis is a severe pneumonia that is usu

170 Invasive aspergillosis is among the most common human fu

171 Diagnosis of invasive aspergillosis is challenging and delays in trea

172 Invasive aspergillosis is characterized by hyphal invasi

173 Invasive aspergillosis is often a consequence of immune

174 rphisms (SNPs) in PTX3 to the development of invasive aspergillosis is unknown.

175 During invasive aspergillosis, mice with a CCR7 deficiency in t

176 Invasive aspergillosis most commonly involves the sinopu

177 that, in the lungs of neutropenic mice with invasive aspergillosis, NK cells were the major populati

178 Invasive aspergillosis occurred in 26 liver transplant r

179 roups (11.0 vs. 7.4 vs. 2.8 days, P=0.0003.) Invasive aspergillosis occurred in 44% of the lowest IgG

180 Invasive aspergillosis occurred significantly earlier af

181 ), tissue-invasive cytomegalovirus (P=0.01), invasive aspergillosis (P=0.001), total fungal infection

182 and an insignificant increase in the rate of invasive aspergillosis (P=0.20) occurred.

183 During invasive aspergillosis, platelets might be involved in i

184 The mortality and morbidity caused by invasive aspergillosis present a major obstacle to the s

185 nd caspofungin (n=40) as primary therapy for invasive aspergillosis (proven or probable) in a prospec

186 Diagnosis of invasive aspergillosis remains a significant problem.

187 ersistently immunosuppressed murine model of invasive aspergillosis resulted in hypovirulence, while

188 KC in the lung in the setting of established invasive aspergillosis results in improved host defense

189 subsets of organ transplant recipients with invasive aspergillosis, such as those with renal failure

190 aluation of therapeutic strategies to combat invasive aspergillosis that closely mimic human disease

191 t we believe is a novel defense mechanism in invasive aspergillosis that is the result of alterations

192 Unlike invasive aspergillosis, the prognosis and outcome of hem

193 tigen detection for cryptococcal disease and invasive aspergillosis, the use of molecular (PCR) diagn

194 ke early therapeutic decisions when treating invasive aspergillosis using changes in biomarkers as a

195 of A. fumigatus and unique susceptibility to invasive aspergillosis via incompletely characterized me

196 The incidence of breakthrough invasive aspergillosis was 1.9% (5/262), all with true-p

197 The risk of invasive aspergillosis was assessed with the use of mult

198 transplant patients with proven or probable invasive aspergillosis was available from the Transplant

199 Invasive aspergillosis was documented in 5.2% (6/116) of

200 lity of galactomannan antigen for diagnosing invasive aspergillosis was evaluated in 154 liver transp

201 n's eggs and leucopenic mice, the outcome of invasive aspergillosis was similar to that described for

202 To study the pathogenesis of invasive aspergillosis, we investigated the interactions

203 To investigate the role of CCR7 during invasive aspergillosis, we used a well-characterized neu

204 nsitivities and specificities for diagnosing invasive aspergillosis were 81.6% and 91.6%, and 76.9% a

205 y failure, malignant organ infiltration, and invasive aspergillosis were associated with higher hospi

206 lungs of cortisone-treated mice during early invasive aspergillosis, whereas gene expression returned

207 Among these infections is invasive aspergillosis, which is a major cause of morbid

208 and 54% were on dialysis before the onset of invasive aspergillosis, which suggest that overall sever

209 nic mice provided a protective effect during invasive aspergillosis, which was further enhanced with

210 sufficient sensitivity for the screening of invasive aspergillosis while maintaining methodological

211 ix hospitalized patients with no evidence of invasive aspergillosis who were receiving antibiotics an

212 A. flavus is the second leading cause of invasive aspergillosis worldwide.

213 lerated and effective against IFIs including invasive aspergillosis, zygomycosis, fusariosis, and cry